Analyst Price Target is $8.00
▲ +3,193.54% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Bionomics in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 3,193.54% upside from the last price of $0.24.
Current Consensus is
Buy
The current consensus among 2 investment analysts is to buy stock in Bionomics. This rating has held steady since August 2023, when it changed from a Moderate Buy consensus rating.
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
Read More
